Get the Stockscreener App
310.79
0.76%
2.35
After Hours:
313.00
2.21
+0.71%
Beone Medicines Ltd Adr stock is traded at $310.79, with a volume of 133.25K.
It is up +0.76% in the last 24 hours and down -1.14% over the past month.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
See More
Previous Close:
$308.44
Open:
$307.42
24h Volume:
133.25K
Relative Volume:
0.50
Market Cap:
$34.50B
Revenue:
$5.36B
Net Income/Loss:
$287.73M
P/E Ratio:
123.19
EPS:
2.5229
Net Cash Flow:
$924.18M
1W Performance:
+12.22%
1M Performance:
-1.14%
6M Performance:
-9.96%
1Y Performance:
+13.11%
1-Day Range:
$306.32
$315.97
1-Week Range:
$280.59
$315.97
52-Week Range:
$196.45
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
310.79 | 34.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Barclays | Overweight |
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
BeOne Medicines (NASDAQ:ONC) Stock Price Down 6.2%Here's Why - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s Why - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewswire Inc.
BeOne Medicines Ltd.Sponsored ADR $ONC Shares Bought by AIA Group Ltd - MarketBeat
Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $401.00 - Defense World
Jain Global LLC Sells 32,244 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 341 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
Capital International Investors Boosts Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Pinpoint Asset Management Singapore Pte. Ltd. Has $1.49 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (ONC) Is Down 15.1% After Surging To GAAP Profitability And Raising 2026 GuidanceHas The Bull Case Changed? - Sahm
JPMorgan Chase & Co. Has $16.63 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
TD Asset Management Inc Takes $9.33 Million Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00 - Defense World
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment - Finviz
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Generali Investments Management Co LLC Takes Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Earnings Miss - Defense World
Here's What Important Indicators Reveal About BeOne Medicines Ltd.Sponsored ADR (ONC) Fourth Quarter Results - Bitget
Here's What Key Metrics Tell Us About BeOne Medicines Ltd.Sponsored ADR (ONC) Q4 Earnings - Yahoo Finance
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum - ChartMill
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
M&G PLC Has $41.17 Million Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Bernstein Remains a Buy on BeOne Medicines AG (ONC) - Finviz
Candriam S.C.A. Sells 67,718 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Trial Wins And Sonrotoclax Clearance Meet Valuation Discount - Sahm
3 Stocks to Buy in February - Finviz
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Finviz
Mirae Asset Global Investments Co. Ltd. Acquires 38,992 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 - Finviz
BeOne Medicines Collaboration Extends Safety Modeling As Shares Trade Below Targets - Sahm
Assessing BeOne Medicines (ONC) Valuation After Expanded InSysBio Collaboration On Clinical Trial Modeling - Sahm
Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative? - simplywall.st
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):